H. Kashiwagi

发表

Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors

David M. Wallace, T. Arrhenius, Jie Cheng, 2004 .

A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.

H. Kashiwagi, Y. Ono, M. Ishigai, 2013, Bioorganic & medicinal chemistry.

Effects of fluorines on nonsecosteroidal vitamin D receptor agonists.

K. Morikami, H. Kashiwagi, Y. Ono, 2013, Bioorganic & medicinal chemistry.

Novel nonsecosteroidal vitamin D3 carboxylic acid analogs for osteoporosis, and SAR analysis.

Takamitsu Kobayashi, H. Kashiwagi, Y. Ono, 2011, Bioorganic & medicinal chemistry.

Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based screening of focused libraries.

K. Morikami, H. Kashiwagi, T. Kamikawa, 2017, Bioorganic & medicinal chemistry letters.

Facile Construction of the 7,8‐Olefin Linkage in Vitamin D3: A Practical Synthesis Benefiting the Vitamin D3 Analog Study

H. Kashiwagi, Y. Ono, Tadakatsu Takahashi, 2006 .

The Direct C-H Difluoromethylation of Heteroarenes Based on the Photolysis of Hypervalent Iodine(III) Reagents That Contain Difluoroacetoxy Ligands.

K. Maruoka, H. Kashiwagi, Ryu Sakamoto, 2017, Organic letters.

Efficient generation of perfluoroalkyl radicals from sodium perfluoroalkanesulfinates and a hypervalent iodine(iii) reagent: mild, metal-free synthesis of perfluoroalkylated organic molecules.

K. Maruoka, S. Moteki, H. Kashiwagi, 2016, Organic & biomolecular chemistry.

Systematic SAR study of the side chain of nonsecosteroidal vitamin D₃ analogs.

K. Morikami, H. Kashiwagi, Y. Ono, 2012, Bioorganic & medicinal chemistry.

Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).

K. Morikami, H. Kashiwagi, M. Irie, 2016, Chemical & pharmaceutical bulletin.

Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).

K. Morikami, H. Kashiwagi, T. Kamikawa, 2016, Bioorganic & medicinal chemistry.

Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).

K. Morikami, H. Kashiwagi, T. Kamikawa, 2016, Bioorganic & medicinal chemistry.